A Study of MRG003 in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2021-03-29
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the safety, efficacy, and pharmacokinetics of
MRG003, as well as immunogenicity as defined by the incidence of anti-drug antibody (ADA) of
MRG003 in patients with advanced solid tumors, including colorectal cancer, squamous cell
carcinoma of head and neck, and nasopharyngeal carcinoma.